The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0280474 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Hongjuan Zheng und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
The aim of the current study was to explore the association between age and outcomes in breast cancer.
Methods
Patients during 2010–2015 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Overall survival (OS) and breast cancer-specific death (BCSD) were taken as endpoints. The restrict cubic spline graph (RCS) was used to explore the relationship between age and outcomes in patients, and the cumulative incidence of BCSD and non-BCSD was calculated using the Gray method. Age-specific gene expression profiles were studied using RNA sequence data from the Cancer Genome Atlas (TCGA) database to explore whether there were young age-related gene or gene sets.
Results
A total of 142,755 patients with breast cancer were included. The hazard ratio (HR) of OS for Patients with stage I-III breast cancer was roughly stable before 53 years old and increased significantly after that, and the HR of BCSD for these patients showed a U-shaped distribution when plotted against age, with patients younger than 50 years and patients older than 70 years experiencing the worst survival. Further stratified analysis according to molecular subtype revealed that the U-shaped distribution of the HR of BCSD with was only found in the Hormone receptor-positive/HER2-negative (HoR+/HER2-) subgroup. The cumulative incidence plots showed that young age was associated with worse BCSD in the breast cancer patients with stage I-III and HoR+/HER2- subgroup. In stage IV breast cancer, there was a linearity of the relationship between poor OS and increasing age. We failed to find any differentially expressed age-specific genes between 20–40 years and 41–60 years groups in 258 patients with stage I-III and HoR+/HER2- subtype.
Conclusion
Young age could predict worse BCSD of patient with stage I-III and HoR+/HER2- breast cancer. The escalating therapy was recommended to young age breast cancer with stage I-III and HoR+/HER2- subtype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China.
- Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China.
- Department of Hepatobiliary Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China.
ORCID-Profile: Jianfei Fu
Zitieren
APA
Zheng, H., Ge, C., Lin, H., Zhou, S., Tang, W., Wang, Q., Zhang, X., Jin, X., Xu, X., Du, J., & Fu, J. (2023). The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups. PLOS ONE. https://doi.org/10.1371/journal.pone.0280474
Vancouver
Zheng H, Ge C, Lin H, Zhou S, Tang W, Wang Q, et al. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups. PLOS ONE. 2023. doi:10.1371/journal.pone.0280474
BibTeX
@article{Zheng2023,
author = {Zheng, Hongjuan and Ge, Chenyang and Lin, Haiping and Zhou, Shishi and Tang, Wanfen and Wang, Qinghua and Zhang, Xia and Jin, Xiayun and Xu, Xifeng and Du, Jinlin and Fu, Jianfei},
title = {The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0280474}
}
EUVIMED